Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K5RX
|
||||
Former ID |
DNC004980
|
||||
Drug Name |
KYS-05050
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C34H37N5O
|
||||
Canonical SMILES |
C1=CC=C(C=C1)CNC(=O)CC2C3=CC=CC=C3N=C(N2C4=CC=C(C=C4)C5<br />=CC=CC=C5)NCCCCCN
|
||||
InChI |
1S/C34H37N5O/c35-22-10-3-11-23-36-34-38-31-17-9-8-16-30(31)32(24-33(40)37-25-26-12-4-1-5-13-26)39(34)29-20-18-28(19-21-29)27-14-6-2-7-15-27/h1-2,4-9,12-21,32H,3,10-11,22-25,35H2,(H,36,38)(H,37,40)
|
||||
InChIKey |
PHOBNPDRNIKURV-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Voltage-dependent T-type calcium channel subunit alpha-1H | Target Info | Inhibitor | [1] | |
Voltage-dependent T-type calcium channel alpha-1G subunit | Target Info | Inhibitor | [1] | ||
KEGG Pathway | MAPK signaling pathway | ||||
Calcium signaling pathway | |||||
Circadian entrainmenthsa04010:MAPK signaling pathway | |||||
Circadian entrainment | |||||
Type II diabetes mellitus | |||||
PANTHER Pathway | Endogenous cannabinoid signaling | ||||
GABA-B receptor II signaling | |||||
Nicotine pharmacodynamics pathway | |||||
Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | ||||
PathWhiz Pathway | Muscle/Heart ContractionPW000564:Muscle/Heart Contraction | ||||
Reactome | NCAM1 interactionsR-HSA-419037:NCAM1 interactions | ||||
WikiPathways | Corticotropin-releasing hormone | ||||
NCAM signaling for neurite out-growthWP1866:NCAM signaling for neurite out-growth | |||||
Nicotine Activity on Chromaffin Cells | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. Epub 2006 Oct 12.Synthesis and biological evaluation of novel T-type calcium channel blockers. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.